Skip to main content
. 2017 Oct 5;22(2):834–848. doi: 10.1111/jcmm.13365

Figure 8.

Figure 8

TAT‐MTScs‐FXN is processed and functional in mice muscle (A) A representative image of frataxin present in mitochondrial fractions obtained from mice treated for 3 weeks—twice a week—with 10 mg/kg TAT‐MTScs‐FXN (lanes 1–6) or vehicle (lanes 7–8 where frataxin is almost undetectable). The same protocol was executed by administrating 4 mg/kg (not shown). Each lane (1–6) represents individual mouse. Unprocessed external TAT‐MTScs‐FXN protein was run in parallel (lane 9). Lower panel shows the levels of COX‐IV that was used as internal mitochondrial marker. The frataxin levels normalized against COX‐IV are shown in (B). Dashed line indicates the frataxin levels of heterozygous, healthy mice. Bars represent mean ± S.E.M., n = 4. In (C), the activity of mitochondrial complex II (succinate dehydrogenase) is shown. Values were obtained in samples of muscle mitochondrial fractions from mice treated with 4 and 10 mg/kg of TAT‐MTScs‐FXN and vehicle. Dashed line indicates the frataxin values for heterozygous, healthy mice. Results are presented as ΔOD at 0–10 min. per total protein (bars represent mean ± S.E.M., n = 4, P < 0.05,anova).